Mercury Laboratories
702.00
-68.00(-8.83%)
Market Cap₹84.24 Cr
PE Ratio19.58
IndustryHealthcare
Company Performance:
1D-8.83%
1M-17.89%
6M-18.37%
1Y-14.69%
5Y-9.27%
View Company Insightsright
More news about Mercury Laboratories
13Aug 25
Mercury Laboratories Reports 183% Jump in Net Profit with Strong Revenue Growth
Mercury Laboratories Limited reported strong financial results for the recent quarter. Total revenue increased by 8.9% to ₹18.32 crore, while net profit after tax surged by 183.3% to ₹96.76 lakh. The EBITDA margin expanded to 13.9% from 10.5%. Revenue from operations grew by 8.7% to ₹18.14 crore. The company's performance was attributed to higher operating leverage, improved cost management, and a favorable product mix. Despite increases in material costs and employee expenses, effective cost control measures led to a 9.4% decrease in other expenses to ₹4.29 crore.
 no imag found
Mercury Laboratories
702.00
-68.00
(-8.83%)
1 Year Returns:-14.69%
Industry Peers
Sun Pharmaceutical
1,620.40
(-3.55%)
Divis Laboratories
6,361.50
(-0.27%)
Torrent Pharmaceuticals
4,117.20
(-0.72%)
Dr Reddys Laboratories
1,317.10
(-1.04%)
Lupin
2,296.10
(-1.93%)
Cipla
1,295.00
(-0.83%)
Mankind Pharma
2,267.40
(-1.11%)
Zydus Life Science
927.40
(-2.00%)
Aurobindo Pharma
1,413.80
(-1.50%)
Glenmark Pharmaceuticals
2,299.50
(-1.52%)